Ultralife Corp (NASDAQ: ULBI) has reported E.P.S. of $0.02 for its third fiscal quarter (ending September 30) versus $0.08 for the same period a year ago — a decline of -75%. This performance was $-0.19 short of the consensus estimate of $0.21. E.P.S. were $0.55 for the latest four quarters through September 30 versus $0.26 for the same period a year ago — an increase of 112%.
Recent Price Action
On 11/8/24, Ultralife Corp (NASDAQ: ULBI) stock suffered a major decline of -14.0%, closing at $7.98. Moreover, exceptionally high trading volume at 607% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has declined -5.1% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, ULBI is expected to be a modest Value Builder.
Ultralife has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Ultralife has a slightly positive Appreciation Score of 66 but a slightly negative Power Rating of 39, and the Neutral Value Trend Rating results.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment